All News
BSR Guidelines for Giant Cell Arteritis
NICE has commissioned an update to the 2010 British Society for Rheumatology guideline for the management of giant cell arteritis, and proposed a total of 19 recommendations for the diagnosis and treatment of GCA.
Read Article
RheumNow Podcast - RWCS Quick Hits (2.14.20)
Dr. Jack Cush reviews the highlights from the 2020 RWCS meeting in Maui, Hawaii.
Read Article
PEXIVAS - Plasma Exhange Fails to Boost Outcomes in Severe AAV
The PEXIVAS study showed that plasma exchange did not reduce the incidence of death or ESKD in patients with severe ANCA–associated vasculitis.
Read Article
Shingles Vaccine Lowers Risk of CVA
Shingles infection has been historically linked to an increased risk of stroke. A new study found that Zoster Vaccine Live, one type of shingles vaccination, may prevent stroke in some older adults.
Read Article
RheumNow Podcast- Best Biologics (2.7.20)
Dr Jack Cush reviews the news and journal articles from the past week on RheumNow.com
Read Article
EULAR Recommendations on Sjögren’s Syndrome
The European League Against Rheumatism (EULAR) has established an international collaborative group (EULAR SS Task Force) to develop the first EULAR evidence and consensus-based recommendations for the management of patients with Sjogens syndrome (SjS).
Read Article
RheumNow Podcast- 2019 EULAR RA Guidelines (1.31.20)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read Article
QD Clinic - "Doc, When Can I Stop?"
QD Clinic - Lessons from the clinic. In this video: Patients stable on a biologic need guidance on when, and if, they can stop their biologic.
Read Article
Steroid-Sparing Effect of Tocilizumab in Refractory Takayasu Arteritis
A controlled clinical trial has shown that giving the IL-6 receptor antibody, tocilizumab (TCZ), to patients with Takayasu arteritis (TAK) results in clinical efficacy and has a steroid sparing efffect.
Read Article
RheumNow Podcast- The Down Side of Steroids (1.17.20)
Dr. Jack Cush reviews the journal reports and news from RheumNow.com.
Be sure to register for RheumNow Live 3/13/2020 in Fort Worth
Rheumnow.live.
TULIP2 - Anifrolumab Succeeds in Lupus
NEJM has published the results of the TULIP2 trial with anifrolumab, an alpha interferon blocker, in the treatment of systemic lupus erythematosus, showing significant improvement (over placebo) in multiple lupus outcome measures, including BICLA, SRI-4, CLASI and others.
Steroids Up the Risk of Organ Damage in SLE
Lancet Rheumatology has reported the results of a multicenter follow-up study of systemic lupus erythematosus (SLE) patients showing that organ damange is linked to glucocorticoid use, independent of clinical or serological disease activity.
Read Article
Treatment of Statin-induced anti-HMGCR myopathy
Statin-induced myositis, often with anti-HMGCR autoantibodies can be difficult to manage, Arthritis Research & Therapy yhas published the experience of 55 patient with HMGCR myopathy, demonstrating that while steroid management may be reasonable in select patients, the use of tr
Read Article
Best of 2019 - 2019 EULAR Guidelines on Antiphospholipid Syndrome Management
A EULAR task force has reviewed the medical literature and developed evidence-based recommendations for the management of antiphospholipid syndrome (APS) in adults. They note that a high-risk antiphospholipid antibody (aPL) profile is associated with greater risk for thrombotic and obstetric APS.
Read Article
Best of 2019 - New EULAR/ACR Classification Criteria for SLE
The European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) have jointly developed new classification criteria for systemic lupus erythematosus (SLE); prompted by the need for criteria that were both highly sensitive and specific. The net result is improved sensitivity and specificity, but the use of positive ANA requirement along with a longer list of weighted criteria ensures its utility in SLE research (including early or latent SLE), but not clinical practice.
Read ArticleRheumNow Podcast – Merry Lupus XMAS (12.20.19)
Dr. Jack Cush reviews the news from the past week on RheumNow.com, just in time for Christmas!
Read Article
Belimumab in Lupus Nephritis
Belimumab has been studied in an active lupus nephritis, phase 3 trial call BLISS-LN and shown to be effective as measured by trial of belimumab for the treatment of active lupus nephritis in adult patients.
Read Article
Is Anifrolumab Good Enough for Systemic Lupus Erythematosus?
The NEJM published favorable results of a phase 3 trial of the alpha interferon inhibitor, anifrolumab, showing it to be superior to placebo in active systemic lupus erythematosus (SLE) patients studied for 48 weeks.
Read Article
Fewer Lupus Flares on Low Dose Steroids
French researchers have shown that patients with systemic lupus erythematosus (SLE) and inactive disease are less likely to flare while taking a 5 mg prednisone maintenance dose.
Read Article
New ACR guidelines for OA hip/knee give a conditional recommendation for Balance exercises. https://t.co/2YLKuhZ92M A systematic review of 11 studies shows Knee OA pts at risk for falls. Risk factors: impaired balance, weakness, comorbidities, # of joints https://t.co/fAzYHtIpEM
Links:
Dr. John Cush RheumNow ( View Tweet)
